Revolutionizing our understanding of the genetic causes and mechanisms of hyperinsulinism, developing diagnostic tools for a precision-medicine approach to treatment, and discovering new treatment options.
The purpose of this study is to look at the safety and tolerability (how well you will react) of the study drug (HM15136) and to determine if it is effective for the treatment of Congenital Hyperinsulinism (HI).
The goals of this research study are to learn more about acute recurrent and chronic pancreatitis in order to better understand the disease in the hopes of enhancing future treatment options.
This study is a 2 period, open label study that will evaluate the safety and efficacy of dasiglucagon in children between the ages of 3 months and 12 years.
The goal of the trial is to test the study drug safety, how your body processes the drug, how the drug affects your body, and see if it can increase your blood sugar.
This study is a randomized, double-blind, placebo-controlled study that will evaluate the safety and efficacy of dasiglucagon in children between the ages of 7 days and 12 months who have congenital hyperinsulinism.
Our team is working on a study to better understand neurological problems, including seizures and developmental delays, that occur in children with hyperinsulinism, including HI/HA syndrome, and type 1 diabetes mellitus.
